Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for Food Reintroduction in EoE
NCT05247866Phase 4Completed
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Jun 2022
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dupilumab in eosinophilic esophagitis (EoE), sponsored by Children's Hospital of Philadelphia. Primary endpoint: Esophageal Eosinophilia (Number of Eosinophils in the Esophagus) at 48 weeks. Started Jun 2022; status: completed.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05247866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05247866.